Overview Phase III Study of 608 in the Treatment of Active Ankylosing Spondylitis in Adults Status: RECRUITING Trial end date: 2027-11-18 Target enrollment: Participant gender: Summary This study will evaluate the efficacy and safety of 608 in patients with AS.Phase: PHASE3 Details Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.